Poster
I-DXd
WCLC 2026 | 12-15 September, 2026
Lung Cancer
A phase 1b/2, open-Label study evaluating gocatamig and ifinatamab deruxtecan for extensive-stage small-cell lung cancer
M. Gutierrez
Poster
Other/Multi
WCLC 2026 | 12-15 September, 2026
Lung Cancer
Clinical impact of NY-ESO expression on the efficacy of immune checkpoint inhibitors in lung squamous cell carcinoma
Motohiro Izumi
Poster
Other/Multi
WCLC 2026 | 12-15 September, 2026
Lung Cancer
Clinical outcomes in patients with advanced large-cell neuroendocrine carcinoma of the lung: A systematic literature review and meta-analysis
C.M. Gay
Oral
T-DXd
WCLC 2026 | 12-15 September, 2026
Lung Cancer
First-line trastuzumab deruxtecan (T-DXd) in metastatic HER2-mutant NSCLC: DESTINY-Lung04 primary results
Julia Rotow
Poster
I-DXd
WCLC 2026 | 12-15 September, 2026
Lung Cancer
Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: Extended safety analysis of IDeate-Lung01
Luis Paz-Ares
Poster
Pipeline Compounds
WCLC 2026 | 12-15 September, 2026
Lung Cancer
KEYMAKER-U01F: Umbrella Study of Novel Therapies in Previously Treated Advanced/Metastatic Nonsquamous KRAS G12C–Mutant NSCLC
B.C. Cho
Poster
Other/Multi
WCLC 2026 | 12-15 September, 2026
Lung Cancer
Protein expression and prognostic value of HER3 and HER2 in a real-world cohort of Danish patients with metastatic non–small-cell lung cancer
K. Zu